A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.

@article{Khaled1999ARE,
  title={A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.},
  author={Hussein Mostafa Khaled and Z K Zekri and Nadia Mahmoud Mokhtar and Nahed M Ali and Tarek Darwish and Inas Anwar Elattar and Rabab Mohamed Gaafar and Mahmoud M. Moawad},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1999},
  volume={10 12},
  pages={
          1489-92
        }
}
BACKGROUND The value of continuous-infusion chemotherapy (EPOCH) vs. the standard CHOP combination was evaluated in 78 patients with previously untreated aggressive non-Hodgkin's lymphoma in a randomized phase III clinical trial. PATIENTS AND METHODS The EPOCH regimen given to 38 patients consisted of the drugs etoposide (50 mg/m2), vincristine (0.4 mg/m2), and doxorubicin (10 mg/m2), all given in a continuous infusion on days 1-4. Cyclophosphamide (750 mg/m2) was administered on day 6 as i.v… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-5 of 5 extracted citations